-6%
Ruxonib is a (JAK) inhibitor indicated for
- The topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 12 years of age and older.
- The topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.